Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Alignment Healthcare, Inc.
High uncertainty: The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-74.3% vs price
Base Case (Median)
-57.3% vs price
Bull Case (75th pct.)
-43.1% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| PE Comparable | $4.49 | -43.1% | Medium (25%) |
| Graham Number | $1.97 | -75.0% | Medium (40%) |
| EV/EBITDA | $3.37 | -57.3% | Medium (20%) |
| EV/FCF | $18.29 | 131.8% | Medium (20%) |
| Earnings Power Value | $2.03 | -74.3% | Medium (50%) |
Based on 5 out of 7 methods, ALHC appears overvalued at the current price of $7.89. The base case fair value of $3.37 implies 57.3% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.